Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ibuzatrelvir co-process API film coated · 1 trial · 11 indications
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | single dose of ibuzatrelvir original tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment B | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment C | EXPERIMENTAL | single dose of ibuzatrelvir of the new tablet formulation dispersed in water and given in the fasted state on Day 1 of the treatment period |
| Treatment D | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fed state on Day 1 of the treatment period |
| Name | Type | Description |
|---|---|---|
| Ibuzatrelvir co-process API film coated tablet | DRUG | original |
| Ibuzatrelvir filmcoated tablet | DRUG | new |
Inclusion criteria: 1. 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs. 2. BMI of 16-32 kg/m2; and a tot...
Ibuzatrelvir is an investigational small molecule being studied for the treatment of Coronavirus Disease 2019 (COVID-19). It is being developed by Pfizer, Inc. (PFE) and is currently in Phase 1 clinical development for this infectious disease indication.
Ibuzatrelvir is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of COVID-19.
Ibuzatrelvir is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of the drug has been completed, and it remains under investigation for the treatment of COVID-19.
Ibuzatrelvir has one completed Phase 1 clinical trial, registered as NCT07552779. This study, conducted in Belgium, evaluated how the drug is taken up into the blood of healthy adults after taking different tablet formulations. The trial enrolled 17 participants.
No, Ibuzatrelvir is not the same as Paxlovid. Paxlovid is a combination of nirmatrelvir and ritonavir, while Ibuzatrelvir is a separate investigational compound. Ibuzatrelvir is being studied as a potential treatment for COVID-19, but it is a distinct drug candidate.